Sygnature Discovery and Pneumolabs Establish A Strategic Alliance

18-May-2012 - United Kingdom

Sygnature Discovery Limited and Pneumolabs (UK) Limited announced they have entered into a strategic alliance.  Under the terms of the agreement, Sygnature and Pneumolabs will collaborate to provide a fully-integrated drug discovery service to accelerate clients’ drug discovery programmes into development.  This new alliance complements Sygnature’s existing strategic alliances with Cyprotex Discovery, a centre of excellence for in vitro ADME/toxicology, and Saretius, a pre-clinical experimental services company offering ‘gold standard’ techniques in pain, metabolic and CNS disorders, inflammatory disease and in vivo pharmacokinetics.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance